AtheroNova files for Ch.11 bankruptcy protection; Oncolytics nabs orphan drug designation;

@FierceBiotech: Bullish ex-Elan chief plots a $43M buy-in for upstart Serenus. Article | Follow @FierceBiotech

@JohnCFierce: Remember when the NVCA wailed over the unsustainable VC model in biotech, the FDA's fossilized review process? Ah, the old days... in 2012. | Follow @JohnCFierce

@DamianFierce: German Merck refers to itself as "Merck KGaA, Darmstadt, Germany" on every reference. We get it. You're German. More | Follow @DamianFierce

> Irvine, CA-based AtheroNova, which had been working on cardio drugs, has filed for Chapter 11 bankruptcy protection. Release

> Canada's Oncolytics Biotech has won an orphan drug designation from the FDA for their drug Reolysin. Release

Medical Device News

@FierceMedDev: UPDATED with interview: FDA approves Actavis intrauterine device to prevent pregnancy. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Boston Sci to acquire Endo's men's health devices for $1.6B. Story | Follow @VarunSaxena2

> Nevro appoints former JJDC head to board as it awaits anticipated FDA approval. More

> In loss for Medtronic, appeals court overturns $102M owed by NuVasive for patent infringement. Story

> Siemens Healthcare accused of faking contracts in China. Report

Pharma News

@FiercePharma: IYCMI yesterday: Medicare urged to crack down on antipsychotic scripts for dementia sufferers. Report | Follow @FiercePharma

@EricPFierce: FDA unloads another 14 observations on Hospira Vizag India plant, further delaying its opening. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: To avoid becoming deal bait, Mylan CEO may have to make another big buy. News | Follow @CarlyHFierce

> Novartis CEO: We can rebuild our good name after 'reputational hit' in Japan. Story

> Genentech's cancer drug supply switch costs more, delays treatment, survey finds. Article

> Gilead's hep C combo Harvoni wins NICE blessing at $58K price. Item

Biotech Research News

> Canadian researchers study a new mechanism of action for cancer metastasis. More

> Scripps investigators ID a key player in disarming chemotherapy. Report

> Glioblastoma project IDs a new approach to brain cancer and understanding EGFR. Article

> Researchers add insights to IL-37's anti-inflammatory potential. More

> Mount Sinai preclinical program flags a potential drug strategy for MS. Story

Pharma Manufacturing News

> Hospitals say Roche supply chain move is affecting patient care. Item

> Pfizer shuttering vitamin C plant in California, 70 workers out of jobs. Report

> Hospira's new India plant again faulted by the FDA. Story

> Companies strike trans-Pacific manufacturing and development agreement. More

> G&W Laboratories buying Teva plant after picking up one from Actavis. Article

Pharma Asia News

> Sun Pharma buys GSK's Tasmania opiates business to expand pain offerings. More

> Gilead moves from Japan to India lining up hep C, HIV licensing deals. Story

> Singapore's TauRx notes Alzheimer's candidate journal publication, but buzz eludes. Article

> Takeda confirms eyeing opportunities in India, elsewhere, in vaccine space. News

> Deadly flu outbreak in Hong Kong gathers pace, prompting vaccination push. More

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.